FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009416404> ?p ?o ?g. }

• W2009416404 abstract "Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed post-injection delirium/sedation syndrome (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/ : NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489" @default.
• W2009416404 created "2016-06-24" @default.
• W2009416404 creator A5031519618 @default.
• W2009416404 creator A5047246416 @default.
• W2009416404 creator A5047400779 @default.
• W2009416404 creator A5068884979 @default.
• W2009416404 creator A5069328349 @default.
• W2009416404 creator A5076026899 @default.
• W2009416404 creator A5079794570 @default.
• W2009416404 creator A5082683482 @default.
• W2009416404 creator A5091835887 @default.
• W2009416404 date "2010-06-10" @default.
• W2009416404 modified "2023-10-02" @default.
• W2009416404 title "Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism" @default.
• W2009416404 cites W1986896280 @default.
• W2009416404 cites W1988430501 @default.
• W2009416404 cites W2009915038 @default.
• W2009416404 cites W2030951340 @default.
• W2009416404 cites W2065746155 @default.
• W2009416404 cites W2071997614 @default.
• W2009416404 cites W2076802558 @default.
• W2009416404 cites W2090791696 @default.
• W2009416404 cites W2149251332 @default.
• W2009416404 cites W2157408003 @default.
• W2009416404 cites W2319806219 @default.
• W2009416404 cites W2411647251 @default.
• W2009416404 cites W2085719905 @default.
• W2009416404 doi "https://doi.org/10.1186/1471-244x-10-45" @default.
• W2009416404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2895590" @default.
• W2009416404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20537130" @default.
• W2009416404 hasPublicationYear "2010" @default.
• W2009416404 type Work @default.
• W2009416404 sameAs 2009416404 @default.
• W2009416404 citedByCount "73" @default.
• W2009416404 countsByYear W20094164042012 @default.
• W2009416404 countsByYear W20094164042013 @default.
• W2009416404 countsByYear W20094164042014 @default.
• W2009416404 countsByYear W20094164042015 @default.
• W2009416404 countsByYear W20094164042016 @default.
• W2009416404 countsByYear W20094164042017 @default.
• W2009416404 countsByYear W20094164042018 @default.
• W2009416404 countsByYear W20094164042019 @default.
• W2009416404 countsByYear W20094164042020 @default.
• W2009416404 countsByYear W20094164042021 @default.
• W2009416404 countsByYear W20094164042022 @default.
• W2009416404 countsByYear W20094164042023 @default.
• W2009416404 crossrefType "journal-article" @default.
• W2009416404 hasAuthorship W2009416404A5031519618 @default.
• W2009416404 hasAuthorship W2009416404A5047246416 @default.
• W2009416404 hasAuthorship W2009416404A5047400779 @default.
• W2009416404 hasAuthorship W2009416404A5068884979 @default.
• W2009416404 hasAuthorship W2009416404A5069328349 @default.
• W2009416404 hasAuthorship W2009416404A5076026899 @default.
• W2009416404 hasAuthorship W2009416404A5079794570 @default.
• W2009416404 hasAuthorship W2009416404A5082683482 @default.
• W2009416404 hasAuthorship W2009416404A5091835887 @default.
• W2009416404 hasBestOaLocation W20094164041 @default.
• W2009416404 hasConcept C118552586 @default.
• W2009416404 hasConcept C177713679 @default.
• W2009416404 hasConcept C185592680 @default.
• W2009416404 hasConcept C2776291583 @default.
• W2009416404 hasConcept C2776412080 @default.
• W2009416404 hasConcept C2776619155 @default.
• W2009416404 hasConcept C2776814716 @default.
• W2009416404 hasConcept C2779753318 @default.
• W2009416404 hasConcept C2780494398 @default.
• W2009416404 hasConcept C42219234 @default.
• W2009416404 hasConcept C43617362 @default.
• W2009416404 hasConcept C71924100 @default.
• W2009416404 hasConcept C72092618 @default.
• W2009416404 hasConcept C98274493 @default.
• W2009416404 hasConceptScore W2009416404C118552586 @default.
• W2009416404 hasConceptScore W2009416404C177713679 @default.
• W2009416404 hasConceptScore W2009416404C185592680 @default.
• W2009416404 hasConceptScore W2009416404C2776291583 @default.
• W2009416404 hasConceptScore W2009416404C2776412080 @default.
• W2009416404 hasConceptScore W2009416404C2776619155 @default.
• W2009416404 hasConceptScore W2009416404C2776814716 @default.
• W2009416404 hasConceptScore W2009416404C2779753318 @default.
• W2009416404 hasConceptScore W2009416404C2780494398 @default.
• W2009416404 hasConceptScore W2009416404C42219234 @default.
• W2009416404 hasConceptScore W2009416404C43617362 @default.
• W2009416404 hasConceptScore W2009416404C71924100 @default.
• W2009416404 hasConceptScore W2009416404C72092618 @default.
• W2009416404 hasConceptScore W2009416404C98274493 @default.
• W2009416404 hasIssue "1" @default.
• W2009416404 hasLocation W20094164041 @default.
• W2009416404 hasLocation W20094164042 @default.
• W2009416404 hasLocation W20094164043 @default.
• W2009416404 hasLocation W20094164044 @default.
• W2009416404 hasOpenAccess W2009416404 @default.
• W2009416404 hasPrimaryLocation W20094164041 @default.
• W2009416404 hasRelatedWork W1995774728 @default.
• W2009416404 hasRelatedWork W2009416404 @default.
• W2009416404 hasRelatedWork W2055929037 @default.
• W2009416404 hasRelatedWork W2138893805 @default.
• W2009416404 hasRelatedWork W2320420952 @default.
• W2009416404 hasRelatedWork W2461798259 @default.
• W2009416404 hasRelatedWork W2914101162 @default.
• W2009416404 hasRelatedWork W2967133130 @default.

• next